UK - EHL Outcomes Registry
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02938156|
Recruitment Status : Unknown
Verified August 2018 by Pratima Chowdary, Royal Free Hospital NHS Foundation Trust.
Recruitment status was: Recruiting
First Posted : October 19, 2016
Last Update Posted : September 4, 2018
Severe haemophilia A and B (SHA, SHB) are inherited bleeding disorders affecting male patients and are characterised by low levels of circulating clotting factors VIII and IX respectively. Clinically low levels present with multiple recurrent bleeds into joints and muscle from the first couple of years of life. In addition patients may present with spontaneous and potentially fatal bleeding into any organ. The mainstay of treatment is replacement with the missing factor in the form of intravenous injections of factor VIII and IX. Clotting factors can be given to treat a bleed or can be given to prevent a bleed, and the latter is termed prophylaxis. Regular prophylaxis is the current standard of care and aims to decrease spontaneous bleeding events and resulting joint damage, and this requires patients to self-infuse factor into their veins two to four times week. Patient's compliance with prescribed regimen and recommendations has a significant influence on outcomes.
Advances in biomolecular and protein engineering have extended the duration of the effect of clotting factor VIII and IX through multiple mechanisms. This extension of the duration of the effect presents the clinician and patients with opportunities to tailor the treatment to their particular needs, circumstances and body other characteristics. It has been suggested that decreasing the frequency of infusions will improve adherence and thus contribute to improved outcomes.
In rare disorders, it is an accepted fact that post-marketing studies are crucial to understand the generalisability of the efficacy and safety outcomes and identify any new safety and efficacy concerns in relation to specific population group. The investigators propose the development of a registry for systematic collection of information with the dual aim of analysing the relationship between patient and treatment characteristics, and outcomes, and simultaneously identify areas for practice development that can improve the overall quality of life experienced by the haemophilia patient community.
|Condition or disease|
|Hemophilia A Hemophilia B|
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||Evaluation of Real World Outcomes With Extended Half-Life Concentrates for Routine Clinical Use in Haemophilia A and B: UK - EHL Outcomes Registry|
|Actual Study Start Date :||December 17, 2016|
|Estimated Primary Completion Date :||October 2019|
|Estimated Study Completion Date :||October 2019|
- Bleed Control [ Time Frame: 2 years post enrolment ]Investigate changes to bleed control using questionnaire & Haemtrack (software package to record therapy received
- Joint Health [ Time Frame: 2 years post enrolment ]Target joint assessment and questionnaire
- EQ-5D-5L [ Time Frame: 2 years post enrolment ]Patient Questionnaire
- HAEM-A-QoL [ Time Frame: 2 years post enrolment ]Patient Questionnaire
- Haemo-QoL [ Time Frame: 2 years post enrolment ]Patient Questionnaire
- Physical Activity QoL [ Time Frame: 2 years post enrolment ]Patient Questionnaire
- Haemoprefer [ Time Frame: 2 years post enrolment ]Patient Questionnaire
- Identify the value of individualised prophylaxis [ Time Frame: 5 years ]Patient questionnaire
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02938156
|Contact: Emal Waqifemail@example.com|
|Contact: Mark Phillipsfirstname.lastname@example.org|
|Principal Investigator:||Pratima Chowdary||Royal Free Hospitals NHS Foundation Trust|